ClinicalTrials.gg
TerminatedNCT02274740Updated Jan 30, 2017

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

A Phase 2 interventional study of LIXISENATIDE AVE0010 and metformin in Type II Diabetes Mellitus, sponsored by Sanofi. Terminated. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-01-30.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision not related to safety reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 47 studies testing lixisenatide in Diabetes Mellitus, Type 2 — 1 open to participants now, 2 under way, none of them phase 3. lixisenatide · Diabetes Mellitus, Type 2.

Enrollment
45th of 47
2 · median 321
Started
2015
the only one that year
Phase 2
4 of 47
none open now
Registered
27th of 47
by date
Lead sponsor
38 of 47
Sanofi

Among the 47 studies testing lixisenatide in Diabetes Mellitus, Type 2, this one is the 45th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 2, and was the 27th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 47 studies testing lixisenatide in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lixisenatide

lixisenatide: first FDA approval 2016 (ADLYXIN), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing lixisenatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the ability of lixisenatide to modulate postprandial hyperlipidemia in particular, the effects on plasma changes in triglycerides.

Secondary Objectives:

The effect of lixisenatide on the following postprandial lipids: apolipoprotein (APO) B48; free fatty acid, lipoprotein distribution, cholesterol, and low-density lipoprotein (LDL) oxidation.

The effect of lixisenatide on chronic low-grade inflammation present in non-insulin dependent diabetes mellitus (NIDDM) and obesity.

The effect of lixisenatide on microvascular dysfunction. To evaluate the effect of lixisenatide on postprandial plasma glucose, insulin and C-peptide and glucagon.

Read the detailed description

Maximum study duration of approximately 2.5 months (study treatment) ± 2 days Day 0 (baseline) plus a 10-week open-label, active-controlled treatment period (Final/End-of-treatment Visit).

03

Conditions studied

  • Type II Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male and female patients, 18-70 years of age.

Diagnosis of Type 2 diabetes treated with metformin and obesity ( [BMI] >30 kg/m\^2) and the following other abnormalities:

  • Abdominal obesity (waist circumference >102 cm in men and >88 cm in women). According to National Cholesterol Education Program-Adult Treatment Panel (NCEP-ATP) III (2001).
  • A1c (HbA1c) ≥7 and ≤8.5% (after Sponsor approval providers might reasonably suggest more stringent A1c goals [such as 6.5%] for selected individual patients, if this can be achieved without significant hypoglycemia or other adverse effects of treatment. Appropriate patients might include those with short duration of diabetes, long , and no significant cardiovascular disease).
  • Hypertriglyceridemia (fasting triglyceride levels between 150 mg/dL and 600 mg/dL, cholesterol \<300 mg/dL. In order to exclude patients who might be suffering from a primitive dyslipidemia).
  • Low high-density lipoprotein (HDL) cholesterol (serum HDL-cholesterol \<40 mg/dL in men and \<50 mg/dL in women).

Written .

Exclusion criteria

Exclusion criteria:

Smoking. Thyroid disease even if under appropriate hormonal replacement therapy or thyroid suppressant (Thyroid Stimulating Hormone [TSH] >5 mU/L with clinical symptoms of hypothyroidism).

Hepatic disease ( [ASAT] or Alanine Aminotransferase [ALAT] >2 times the ).

Renal disease (serum creatinine >1.7 times the upper limit of normal). A history of coronary heart disease, cerebrovascular disease, or peripheral arterial disease in the 6 months before enrollment.

History of . Use of lipid lowering therapy. Systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg. Triglycerides >600 mg/dL. History of chronic pancreatitis or of idiopathic acute pancreatitis.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    lixisenatide

    Lixisenatide injection should be performed in the morning, within 1 hour (ie, 0-60 minutes), prior to breakfast (or standardized meal). Lixisenatide is to be started with once daily injections of 10 μg per day for 2 weeks then to be continued by the maintenance dose (8 weeks) of 20 μg/d up to the end of the treatment period.

    Drug: LIXISENATIDE AVE0010 · Drug: metformin

  • No intervention
    metformin

    Greater than or equal than 1.5 g/day as background therapy for 10 weeks

Interventions

  • Pharmaceutical form:solution Route of administration: subcutaneous

  • Pharmaceutical form:tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min)

    Time frame: After 10 weeks of treatment

Secondary outcomes

  1. Change from baseline in plasma triglyceride

    Time frame: 2 days after the basal test and after 10 weeks of treatment

  2. Change from baseline in plasma cholesterol

    Time frame: 2 days after the basal test and after 10 weeks of treatment

  3. Change from baseline in APO B48

    Time frame: 2 days after the basal test and after 10 weeks of treatment

  4. Change from baseline in free fatty acid levels

    Time frame: 2 days after the basal test and after 10 weeks of treatment

  5. Change from baseline in lipoprotein distribution

    Time frame: 2 days after the basal test and after 10 weeks of treatment

  6. Change from baseline in LDL oxidation

    Time frame: 2 days after the basal test and after 10 weeks of treatment

  7. Change from baseline in postprandial plasma glucose

    Time frame: 2 days after the basal test and after 10 weeks of treatment

  8. Change from baseline in insulin

    Time frame: 2 days after the basal test and after 10 weeks of treatment

  9. Change from baseline in C-peptide

    Time frame: 2 days after the basal test and after 10 weeks of treatment

  10. Change from baseline in low grade inflammation (cytokines and stress oxidative markers)

    Time frame: 2 days after the basal test and after 10 weeks of treatment

  11. Change in baseline coronary flow reserve to assess the effect of lixisenatide on microvascular dysfunction

    Time frame: 2 days after the basal test and after 10 weeks of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2014
First posted
Oct 24, 2014
Start
Apr 2015
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Last update
Jan 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02274740
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 24, 2014
Start date
Apr 2015
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Jan 30, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lixisenatide · Metformin

Start the discussion